Highlights: -One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms -New Eluvia drug-eluting stent shows 94.4% primary patency rate at nine months -Michael Dake: Arch branded device -Andrew Holden: Bioresorbable stents -Profile: Janet Powell
